SEARCH:   Advanced

Blood, 1 July 2006, Vol. 108, No. 1, pp. 28-37. Prepublished online as a Blood First Edition Paper on March 7, 2006; DOI 10.1182/blood-2006-01-0092. This Article Full Text Full Text (PDF) All Versions of this Article: 2006-01-0092v1 108/1/28    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hughes, T. Articles by Goldman, J. M. Search for Related Content PubMed PubMed Citation Articles by Hughes, T. Articles by Goldman, J. M. Related Collections Neoplasia Oncogenes and Tumor Suppressors Reviews in Translational Hematology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW IN TRANSLATIONAL HEMATOLOGY Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Timothy Hughes, Michael Deininger, Andreas Hochhaus, Susan Branford, Jerald Radich, Jaspal Kaeda, Michele Baccarani, Jorge Cortes, Nicholas C. P. Cross, Brian J. Druker, Jean Gabert, David Grimwade, Rüdiger Hehlmann, Suzanne Kamel-Reid, Jeffrey H. Lipton, Janina Longtine, Giovanni Martinelli, Giuseppe Saglio, Simona Soverini, Wendy Stock, and John M. Goldman From the Institute of Medical and Veterinary Science, Adelaide, Australia; Department of Hematology/Medical Oncology, Oregon Health & Science University Cancer Institute, Portland, OR; Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany; Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom; Institute of Hematology and Medical Oncology "Seragnoli," University of Bologna, Italy; Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX; National Genetics Reference Laboratory, University of Southampton, Salisbury, United Kingdom; Assistance Publique des Hopitaux de Marseille (APHM) and Equipe de Recherche Technologique (ERT), University de la Mediterranée, Marseille, France; Department of Medical and Molecular Genetics, King's College, London, United Kingdom; Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada; Department of Pathology, Brigham and Women's Hospital, Boston, MA; Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy; Department of Medicine, University of Chicago, Chicago, IL; and the Hematology Branch, National Heart, Lung & Blood Institute, National Institutes of Health (NIH), Bethesda, MD. The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the total leukemiacell mass and the degree to which BCR-ABL transcripts are reduced by therapy correlates with progression-free survival. Because a rising level of BCR-ABL is an early indication of loss of response and thus the need to reassess therapeutic strategy, regular molecular monitoring of individual patients is clearly desirable. Here we summarize the results of a consensus meeting that took place at the National Institutes of Health (NIH) in Bethesda in October 2005. We make suggestions for (1) harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR-ABL transcript levels on an internationally agreed scale; (2) using serial RQ-PCR results rather than bone marrow cytogenetics or fluorescence in situ hybridization (FISH) for the BCR-ABL gene to monitor individual patients responding to treatment; and (3) detecting and reporting Philadelphia (Ph) chromosome-positive subpopulations bearing BCR-ABL kinase domain mutations. We recognize that our recommendations are provisional and will require revision as new evidence emerges. (Blood. 2006;108:28-37) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers, M. Molimard, M. Krajinovic, and F.-X. Mahon Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood, September 1, 2008; 112(5): 2024 - 2027. [Abstract] [Full Text] [PDF] H. de Lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al. Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis J. Clin. Oncol., July 10, 2008; 26(20): 3358 - 3363. [Abstract] [Full Text] [PDF] D. Meirow, I. Hardan, J. Dor, E. Fridman, S. Elizur, H. Ra'anani, E. Slyusarevsky, N. Amariglio, E. Schiff, G. Rechavi, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients Hum. Reprod., May 1, 2008; 23(5): 1007 - 1013. [Abstract] [Full Text] [PDF] G. Wertheim and A. Bagg Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies J. Mol. Diagn., May 1, 2008; 10(3): 198 - 202. [Abstract] [Full Text] [PDF] F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome Haematologica, May 1, 2008; 93(5): 770 - 774. [Abstract] [Full Text] [PDF] T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib PNAS, April 8, 2008; 105(14): 5507 - 5512. [Abstract] [Full Text] [PDF] L. K. Kenealy, C. B. Christenson, and C. B. Williams Current Therapies for Chronic Myeloid Leukemia Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125. [Abstract] [PDF] J. Laudadio, M. W.N. Deininger, M. J. Mauro, B. J. Druker, and R. D. Press An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy J. Mol. Diagn., March 1, 2008; 10(2): 177 - 180. [Abstract] [Full Text] [PDF] W. Deenik, B. van der Holt, G. E. G. Verhoef, W. M. Smit, M. J. Kersten, H. C. Kluin-Nelemans, L. F. Verdonck, A. Ferrant, A. V. M. B. Schattenberg, J. J. W. M. Janssen, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia Blood, March 1, 2008; 111(5): 2581 - 2588. [Abstract] [Full Text] [PDF] H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood, February 15, 2008; 111(4): 1774 - 1780. [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] T. Lundan, V. Juvonen, M. C. Mueller, S. Mustjoki, T. Lakkala, V. Kairisto, A. Hochhaus, S. Knuutila, and K. Porkka Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 178 - 185. [Abstract] [Full Text] [PDF] T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica, February 1, 2008; 93(2): 186 - 192. [Abstract] [Full Text] [PDF] G. Saglio, F. Pane, and G. Martinelli State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317. [Abstract] [Full Text] [PDF] M. W.N. Deininger Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323. [Abstract] [Full Text] [PDF] R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response Clin. Cancer Res., October 15, 2007; 13(20): 6136 - 6143. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] T. O'Hare, C. A. Eide, and M. W. N. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood, October 1, 2007; 110(7): 2242 - 2249. [Abstract] [Full Text] [PDF] E. Callet-Bauchu, G. Salles, S. Gazzo, S. Dalle, F. Berger, and S. Hayette Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sezary syndrome Haematologica, September 1, 2007; 92(9): 1277 - 1278. [Abstract] [Full Text] [PDF] T. Zhang, S. Grenier, B. Nwachukwu, C. Wei, J. H. Lipton, S. Kamel-Reid, and the Association for Molecular Pathology Hematopath Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring: Summary and Recommendations J. Mol. Diagn., September 1, 2007; 9(4): 421 - 430. [Abstract] [Full Text] [PDF] E. S. Winn-Deen, B. Helton, R. Van Atta, W. Wong, J. Peralta, J. Wang, G. J. Tsongalis, D. Belloni, D. Chan, J. R. Eshleman, et al. Development of an Integrated Assay for Detection of BCR-ABL RNA Clin. Chem., September 1, 2007; 53(9): 1593 - 1600. [Abstract] [Full Text] [PDF] C. A. Schiffer BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265. [Full Text] [PDF] C. A. Schiffer What if conventional-dose imatinib fails? Blood, June 15, 2007; 109(12): 5068 - 5069. [Full Text] [PDF] G. Volpe, A. Cignetti, C. Panuzzo, M. Kuka, K. Vitaggio, M. Brancaccio, G. Perrone, M. Rinaldi, G. Prato, M. Fava, et al. Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches Cancer Res., June 1, 2007; 67(11): 5300 - 5307. [Abstract] [Full Text] [PDF] J. V. Jovanovic, J. Score, K. Waghorn, D. Cilloni, E. Gottardi, G. Metzgeroth, P. Erben, H. Popp, C. Walz, A. Hochhaus, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia Blood, June 1, 2007; 109(11): 4635 - 4640. [Abstract] [Full Text] [PDF] R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel, A. Hochhaus, J. Hasford, H.-J. Kolb, T. Lahaye, O. Maywald, A. Reiter, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia Blood, June 1, 2007; 109(11): 4686 - 4692. [Abstract] [Full Text] [PDF] S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M.-A. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Begaud, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood, April 15, 2007; 109(8): 3496 - 3499. [Abstract] [Full Text] [PDF] I. Iacobucci, L. Galletti, M. Amabile, S. Soverini, M. Baccarani, and G. Martinelli Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio Haematologica, March 1, 2007; 92(3): 429 - 430. [Abstract] [Full Text] [PDF] M. Hertzberg and D. McDonald Optimizing fusion transcript monitoring in CML Blood, March 1, 2007; 109(5): 2263 - 2263. [Full Text] [PDF] T. Hughes, S. Branford, and J. M. Goldman Response: Reliability of PCR for BCR-ABL transcripts Blood, March 1, 2007; 109(5): 2263 - 2264. [Full Text] [PDF] S. Branford Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice Hematology, January 1, 2007; 2007(1): 376 - 383. [Abstract] [Full Text] [PDF] P. Rousselot, F. Huguet, D. Rea, L. Legros, J. M. Cayuela, O. Maarek, O. Blanchet, G. Marit, E. Gluckman, J. Reiffers, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood, January 1, 2007; 109(1): 58 - 60. [Abstract] [Full Text] [PDF] H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker, and M. W. Deininger Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood, October 1, 2006; 108(7): 2332 - 2338. [Abstract] [Full Text] [PDF] S. K. Kathula, S.-C. Chu, J.-L. Tang, C.-C. Li, C. L. Sawyers, M. Talpaz, and E. Bleickardt Dasatinib in chronic myelogenous leukemia. N. Engl. J. Med., September 7, 2006; 355(10): 1062 - 1063. [Full Text] [PDF] T. Hughes ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring Hematology, January 1, 2006; 2006(1): 211 - 218. [Abstract] [Full Text] [PDF] M. J. Mauro Defining and Managing Imatinib Resistance Hematology, January 1, 2006; 2006(1): 219 - 225. [Abstract] [Full Text] [PDF] J. F. Apperley Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation Hematology, January 1, 2006; 2006(1): 226 - 232. [Abstract] [Full Text] [PDF]